Certik and YZi Labs have announced a $1 million audit grant aimed at strengthening security for early-stage Web3 startups. The initiative supports founders enteringCertik and YZi Labs have announced a $1 million audit grant aimed at strengthening security for early-stage Web3 startups. The initiative supports founders entering

Certik and YZi Labs Launch $1M Audit Fund to Strengthen Early Web3 Security

2026/01/07 12:56
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

Certik and YZi Labs have announced a $1 million audit grant aimed at strengthening security for early-stage Web3 startups. The initiative supports founders entering the earliest and most vulnerable phase of development. It adds funded audits directly into the incubation process.

Certik and YZi Labs have announced a $1 million audit grant aimed at strengthening security for early-stage Web3 startups. The initiative supports founders entering the earliest and most vulnerable phase of development. It adds funded audits directly into the incubation process.

The grant will be subsidized audits of smart contracts. It will also have Certik Skynet surveillance and AI-assisted security scanning. The services have been focused on Web3, artificial intelligence, and biotechnology team building.

The program belongs to EASY Residency of YZi Labs. The model of incubation is designed with long-term value creation rather than the quick launch of tokens. It provides international assistance to teams operating in high-risk, high-innovation industries.

https://twitter.com/CertiK/status/2008543810159341967

Certik’s $1M Support for EASY Residency Teams

Under the partnership, Certik will invest the entire amount of $1 million in startups that have been chosen under EASY Residency. This allocation is expected to minimize tradeoffs at early stages of security. It stimulates teams to engage in capturing products prior to delivery to actual users.

YZi Labs will also provide access to the founders to the audit and monitoring teams of Certik. This is aimed at incorporating security at an early stage of the product. The purpose of this approach is to find out vulnerabilities in advance.

Ella Zhang, the head of YZi Labs, noted that the founders need to concentrate on product requirements and not on security issues. She pointed out that the program enables security professionals to control risk. Zhang further said this will ease the pressure on early builders.

Certik CEO Ronghui Gu pointed to the purpose of the partnership. He explained that it will introduce safety into the development of new Web3 companies. Gu stressed that the partnership focuses on increasing standards of development.

Also Read: Ripple Rolls Out XRPL 3.0.0 With Major Escrow Accounting Breakthrough

The plan comes at a time when exploits and porosity of protocols are still affecting the industry. The losses have made security a top priority in development. Early-stage protection is being considered as an essential element rather than a post-launch correction.

EASY Residency Expands Into Global Innovation Hubs

EASY Residency has grown to various world centers. These are Dubai, San Francisco, New York, and Singapore. The program offers capital, mentorship, and currently direct security assistance.

The residency will give up to 500,000 to startups. They also get access to the advice of industry experts in crypto, AI, and biotech. This entails institutionalized assistance that is in line with the long-term objectives.

https://twitter.com/yzilabs/status/1953281394693513679

Certik has been auditing thousands of projects since 2017. It oversees hundreds of billions of dollars in digital assets. This has been discovered to have a lot of bugs in its audits before live implementation.

The joint venture is seeking to shift the time when security can be a part of the startup cycle. Audits are not done late, they are moved to the beginning of development. This leads to the inflow of new players.

Also Read: Polymarket Shocks Crypto Market with Taker Fees on 15-Minute Trades

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09